Category
All topics Articles White papers Brochures
Language
All languages English French
Sort by
Most recent Oldest A–Z

120 items

Revised EU GMP Annex 19: What Pharmaceutical Companies Need to Know About Reference and Retention Samples
November 12, 2026
English
Revised EU GMP Annex 19: What Pharmaceutical Companies Need to Know About Reference and Retention Samples next-arrow
"Annex 1 has an official reading guide. Is your CCS ready for it?"
November 11, 2026
English
"Annex 1 has an official reading guide. Is your CCS ready for it?" next-arrow
Lessons from AI in Pharma 2026: The Role of Digital Quality
November 10, 2026
English
Lessons from AI in Pharma 2026: The Role of Digital Quality next-arrow
Six regulatory points requiring attention from food supplement operators
November 04, 2026
English
Six regulatory points requiring attention from food supplement operators next-arrow
European JCA: the challenge is not simply having evidence, but knowing how to address each PICO
November 03, 2026
English
European JCA: the challenge is not simply having evidence, but knowing how to address each PICO next-arrow
Beyond the Molecule: Why Value-Added Medicines Win (or Lose) Market by Market
November 01, 2026
English
Beyond the Molecule: Why Value-Added Medicines Win (or Lose) Market by Market next-arrow
From SPF Questions to Product Recalls: The Medical Information Role in Sunscreen
October 08, 2026
English
From SPF Questions to Product Recalls: The Medical Information Role in Sunscreen next-arrow
Lean Lab 2026: Laboratory Transformation Goes International
October 05, 2026
English
Lean Lab 2026: Laboratory Transformation Goes International next-arrow
CBD Novel Foods: Regulatory Progress in Both the EU and UK
October 05, 2026
English
CBD Novel Foods: Regulatory Progress in Both the EU and UK next-arrow
“The rarest thing about rare diseases should be their prevalence, not patients' access to appropriate care, innovation and treatment."
October 01, 2026
English
“The rarest thing about rare diseases should be their prevalence, not patients' access to appropriate care, innovation and treatment." next-arrow
From laggard to front-runner: how AI is reshaping pharmaceutical Market Access
September 30, 2026
English
From laggard to front-runner: how AI is reshaping pharmaceutical Market Access next-arrow
EMA Stability Guideline Rev.3: Why It Changes the Way We Manage Post-Approval Variations in 2026
September 23, 2026
English
EMA Stability Guideline Rev.3: Why It Changes the Way We Manage Post-Approval Variations in 2026 next-arrow
Responding to TGA GMP Non-Compliance Notifications: What Sponsors Need to Know
September 16, 2026
English
Responding to TGA GMP Non-Compliance Notifications: What Sponsors Need to Know next-arrow
What makes clinical evidence trustworthy?
September 16, 2026
English
What makes clinical evidence trustworthy? next-arrow
Your EU Dossier Is Not GCC-Ready: What Sponsors Need to Know in 2026
September 15, 2026
English
Your EU Dossier Is Not GCC-Ready: What Sponsors Need to Know in 2026 next-arrow
1 2 3 4 5 6 7 8 Next